Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
BackgroundAge-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involv...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1467160/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526966897868800 |
|---|---|
| author | Settimio Rossi Carlo Gesualdo Ernesto Marano Raffaele Perrotta Maria Consiglia Trotta Antonio Del Giudice Francesca Simonelli |
| author_facet | Settimio Rossi Carlo Gesualdo Ernesto Marano Raffaele Perrotta Maria Consiglia Trotta Antonio Del Giudice Francesca Simonelli |
| author_sort | Settimio Rossi |
| collection | DOAJ |
| description | BackgroundAge-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy. The aim of this study is to provide the real-life anatomical-functional and safety results, after 1 year of treatment experience with Brolucizumab.MethodsThis is a retrospective observational real-life study in which 44 patients (44 eyes) diagnosed with nAMD and treated with Brolucizumab were enrolled. We identified two groups: group 1 (24 treatment-naïve eyes) that received a loading dose of 3 monthly intravitreal injections of Broluciziumab 6 mg (0.05 mL solution) + Q8w/Q12w regimen, and a Group 2 (20 non-naïve eyes) which performed 1 injection + ProReNata (PRN) scheme. Monthly, all participants underwent comprehensive ophthalmological evaluation until 12 months follow-up.ResultsWe observed a significant improvement in best corrected visual acuity (39 ± 15 L vs. 30 ± 17 L; p < 0.01) and central retinal thickness (265 ± 89 μ vs. 360 ± 129 μ; p < 0.0001) at the end of follow-up without any differences between treatment-naïve and non-naïve patients. These results were obtained with a low number of injections (3.7 ± 1.9) with only one case of intraocular drug-related adverse event. Finally, the presence of subretinal hyperreflective material correlates with lower visual recovery.DiscussionOur findings highlight the efficacy of Brolucizumab in managing wet-AMD and suggest its role for long-term efficacy in stabilizing retinal exudation and fluid accumulation, resulting in improved visual prognosis. |
| format | Article |
| id | doaj-art-91b823c0e00d47cba608f0920b7b833b |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-91b823c0e00d47cba608f0920b7b833b2025-01-16T08:18:50ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14671601467160Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal BrolucizumabSettimio Rossi0Carlo Gesualdo1Ernesto Marano2Raffaele Perrotta3Maria Consiglia Trotta4Antonio Del Giudice5Francesca Simonelli6Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania “Luigi Vanvitelli”, Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania “Luigi Vanvitelli”, Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania “Luigi Vanvitelli”, Naples, ItalyEye Unit, G. Rummo Hospital, Benevento, ItalyDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania “Luigi Vanvitelli”, Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania “Luigi Vanvitelli”, Naples, ItalyBackgroundAge-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy. The aim of this study is to provide the real-life anatomical-functional and safety results, after 1 year of treatment experience with Brolucizumab.MethodsThis is a retrospective observational real-life study in which 44 patients (44 eyes) diagnosed with nAMD and treated with Brolucizumab were enrolled. We identified two groups: group 1 (24 treatment-naïve eyes) that received a loading dose of 3 monthly intravitreal injections of Broluciziumab 6 mg (0.05 mL solution) + Q8w/Q12w regimen, and a Group 2 (20 non-naïve eyes) which performed 1 injection + ProReNata (PRN) scheme. Monthly, all participants underwent comprehensive ophthalmological evaluation until 12 months follow-up.ResultsWe observed a significant improvement in best corrected visual acuity (39 ± 15 L vs. 30 ± 17 L; p < 0.01) and central retinal thickness (265 ± 89 μ vs. 360 ± 129 μ; p < 0.0001) at the end of follow-up without any differences between treatment-naïve and non-naïve patients. These results were obtained with a low number of injections (3.7 ± 1.9) with only one case of intraocular drug-related adverse event. Finally, the presence of subretinal hyperreflective material correlates with lower visual recovery.DiscussionOur findings highlight the efficacy of Brolucizumab in managing wet-AMD and suggest its role for long-term efficacy in stabilizing retinal exudation and fluid accumulation, resulting in improved visual prognosis.https://www.frontiersin.org/articles/10.3389/fmed.2024.1467160/fullage-related macular degenerationintravitreal injectionbrolucizumabreal-lifeneovascularization |
| spellingShingle | Settimio Rossi Carlo Gesualdo Ernesto Marano Raffaele Perrotta Maria Consiglia Trotta Antonio Del Giudice Francesca Simonelli Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab Frontiers in Medicine age-related macular degeneration intravitreal injection brolucizumab real-life neovascularization |
| title | Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| title_full | Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| title_fullStr | Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| title_full_unstemmed | Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| title_short | Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| title_sort | treatment of neovascular age related macular degeneration one year real life results with intravitreal brolucizumab |
| topic | age-related macular degeneration intravitreal injection brolucizumab real-life neovascularization |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1467160/full |
| work_keys_str_mv | AT settimiorossi treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT carlogesualdo treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT ernestomarano treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT raffaeleperrotta treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT mariaconsigliatrotta treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT antoniodelgiudice treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab AT francescasimonelli treatmentofneovascularagerelatedmaculardegenerationoneyearrealliferesultswithintravitrealbrolucizumab |